- Total Do-It-Yourself Portfolios with SNN:
- john ray Portfolio 1
- 10 Innovators
- nuclearbikeman Portfolio 1
- SUPRATRADE BLACK ROSE
- dale butterill Portfolio 1
- BIONIC WOMAN....we can rebuild her!
- stocks currently trading
- Ben's First Portfolio
- beach house on the point
- show more
- 18
- Ken Mattus Portfolio 1
- Orthopedic device makers back in play
- kf long term growth
- DKRJC1
- Conference Calls for October 2007 Nymph Style
- Better than buying beer and doughnuts
- Cramer's Marine Field Manual Recession Stock Picks
- Rags to Riche$
- PART 1 JPMorgan 27th Annual Healthcare Conf 1/12/09..1st Day Reporting Companies..Nymph Take
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:thewookie |
Date:03 10 09 |
Exposure to aging baby boomers running themselves into the ground. |
|
Not yet rated
Rate now:
|
|
By:holden33 |
Date:12 20 08 |
baby boomers aging new products coming |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:07 10 08 |
Smith & Nephew has a diversified portfolio of health care businesses. It gets 37% of its revenues from orthopedic reconstruction and it has a orthopedic trauma, endoscopy, and advanced wound care business as well. Cramer said all of its businesses are good and stable. |
|
Not yet rated
Rate now:
|
|
Date:11 19 07 |
|
It's not drugs, it's not hospitals, it's the indispensible business of health care supplies. |
|
Not yet rated
Rate now:
|
|
By:kfwinona |
Date:04 18 07 |
projected growth of orthopedics markets; specific hip and shoulder innovations; dividend history and company history |
|
Not yet rated
Rate now:
|
|
By:arnabdgp |
Date:04 06 07 |
Last month, Smith and Nephew agreed to buy Swiss-based Plus Orthopaedics and leapt over Biomet to become the world's fourth largest hip and knee implant company, grabbing about 12% of the market. |
|
Not yet rated
Rate now:
|
|
By:Guest |
Date:03 28 07 |
Smith & Nephew (SNN), which just acquired Plus Orthopedics. That deal moves the London company into the No. 4 slot in the worldwide orthopedics market. As in most markets, the biggest share of the profits go to the top players, so the company's move up the orthopedics food chain will be a significant driver of increased profit margins in an orthopedics market that will see big growth as the world's population ages. |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |








